SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 208 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2015. The put-call ratio across all filers is 0.97 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,882 | -71.4% | 1,374 | -68.9% | 0.00% | -75.0% |
| Q2 2023 | $132,595 | +276139.6% | 4,411 | +232.4% | 0.00% | +100.0% |
| Q1 2023 | $48 | +433.3% | 1,327 | +389.7% | 0.00% | – |
| Q4 2022 | $9 | -100.0% | 271 | -92.9% | 0.00% | -100.0% |
| Q3 2022 | $130,000 | +94.0% | 3,832 | +65.0% | 0.00% | 0.0% |
| Q2 2022 | $67,000 | +509.1% | 2,322 | +571.1% | 0.00% | – |
| Q1 2022 | $11,000 | -88.2% | 346 | -89.2% | 0.00% | -100.0% |
| Q4 2021 | $93,000 | +257.7% | 3,189 | +228.1% | 0.00% | +100.0% |
| Q3 2021 | $26,000 | -67.5% | 972 | -62.8% | 0.00% | -50.0% |
| Q2 2021 | $80,000 | -40.7% | 2,616 | -49.1% | 0.00% | 0.0% |
| Q1 2021 | $135,000 | +206.8% | 5,141 | +196.3% | 0.00% | +100.0% |
| Q4 2020 | $44,000 | -93.6% | 1,735 | -94.8% | 0.00% | -87.5% |
| Q3 2020 | $689,000 | +231.2% | 33,066 | +277.6% | 0.01% | -11.1% |
| Q2 2020 | $208,000 | +1286.7% | 8,758 | +2930.4% | 0.01% | +800.0% |
| Q3 2018 | $15,000 | +200.0% | 289 | +189.0% | 0.00% | – |
| Q1 2018 | $5,000 | -95.7% | 100 | -96.5% | 0.00% | -100.0% |
| Q3 2017 | $115,000 | +271.0% | 2,873 | +302.9% | 0.01% | +125.0% |
| Q2 2017 | $31,000 | +933.3% | 713 | +613.0% | 0.00% | – |
| Q1 2017 | $3,000 | -93.5% | 100 | -97.1% | 0.00% | -100.0% |
| Q4 2015 | $46,000 | +142.1% | 3,455 | +156.1% | 0.01% | +250.0% |
| Q3 2015 | $19,000 | +18.8% | 1,349 | +46.9% | 0.00% | +100.0% |
| Q2 2015 | $16,000 | +77.8% | 918 | +25.8% | 0.00% | 0.0% |
| Q1 2015 | $9,000 | -83.6% | 730 | -88.9% | 0.00% | -80.0% |
| Q4 2014 | $55,000 | +5400.0% | 6,598 | +6432.7% | 0.01% | – |
| Q3 2014 | $1,000 | – | 101 | +1022.2% | 0.00% | – |
| Q2 2014 | $0 | -100.0% | 9 | -97.6% | 0.00% | – |
| Q1 2014 | $3,000 | -81.2% | 369 | -82.7% | 0.00% | -100.0% |
| Q4 2013 | $16,000 | -20.0% | 2,133 | -24.6% | 0.00% | +50.0% |
| Q3 2013 | $20,000 | -68.8% | 2,828 | -71.7% | 0.00% | -60.0% |
| Q2 2013 | $64,000 | – | 10,002 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |